S708 - legislation to require CMS to issue a dear Medicaid director letter concerning precision medicine for depression
Regulations governing Medicare Advantage plans and the use of prior authorization
FDA rulemaking to regulate laboratory developed tests
Duration: September 1, 2018
to
present
General Issues: Medicare/Medicaid , Medical/Disease Research/Clinical Labs , Budget/Appropriations , Health Issues , Veterans , Copyright/Patent/Trademark
Spending: about $5,046,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2018: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Centers For Medicare and Medicaid Services (CMS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Kimberly Linthicum
Leg Director, Rep Bob Franks (1997-2000) Leg Correspondent, Rep Charles Taylor (1997), Leg Correspondent, Rep Bill Martini (1995-1996)
Leg Director, Rep Bob Franks (1197-2000)
Leg Correspondent, Rep Charles Taylor (1997)
Leg Correspondent, Rep Bill Martini (1995-1996)
Leg Director, Rep Bob Franks (1997-2000)
Leg Correspondent, Rep Charles Taylor (1997)
Leg Correspondent, Rep Bill Martini (1995-1996)
Leg Director, Rep Bob Franks (1997-2000) Leg Correspondent, Rep Charles Taylor (1997) Leg Correspondent, Rep Bill Martini (1995-1996)
Leg Director, Rep Bob Franks (1197-2000) Leg Correspondent, Rep Charles Taylor (1997) Leg Correspondent, Rep Bill Martini (1995-1996)
Kimberly Linthicum Myriad
n/a
Paul Sheives
n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, MYRIAD GENETICS, INC. had in-house lobbyists. The report was filed on April 22.
Original Filing: 301571081.xml
Lobbying Issues
S708 - legislation to require CMS to issue a dear Medicaid director letter concerning precision medicine for depression
Regulations governing Medicare Advantage plans and the use of prior authorization
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FDA rulemaking to regulate laboratory developed tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2023
In Q4, MYRIAD GENETICS, INC. had in-house lobbyists. The report was filed on Jan. 22.
Original Filing: 301540488.xml
Lobbying Issues
S708 - legislation to require CMS to issue a dear Medicaid director letter concerning precision medicine for depression
Regulations governing Medicare Advantage plans and the use of prior authorization
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FDA rulemaking to regulate laboratory developed tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2023
In Q3, MYRIAD GENETICS, INC. had in-house lobbyists. The report was filed on Oct. 19, 2023.
Original Filing: 301509080.xml
Lobbying Issues
H.R. 4366, the Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2024 - report language related to precision medicine for treatment of depression in veterans
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S708 - legislation to require CMS to issue a dear Medicaid director letter concerning precision medicine for depression
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2023
In Q2, MYRIAD GENETICS, INC. had in-house lobbyists. The report was filed on July 17, 2023.
Original Filing: 301478683.xml
Lobbying Issues
H.R. 4366, the Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2024 - report language related to precision medicine for treatment of depression in veterans
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S708 - legislation to require CMS to issue a dear Medicaid director letter concerning precision medicine for depression
H.R. 4531, the Support for Patients and Communities Reauthorization Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 3561, the PATIENT Act of 2023, provisions related to lab price reporting
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2023
In Q1, MYRIAD GENETICS, INC. had in-house lobbyists. The report was filed on April 19, 2023.
Original Filing: 301458831.xml
Lobbying Issues
FY2024 MilCon VA Appropriations bills not yet introduced; provisions related to precision medicine for treatment of depression in veterans
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S708 - legislation to require CMS to issue a dear medicaid director letter concerning precision medicine for depression
Legislation not introduced related to in person visits for high-cost lab tests ordered in Medicare
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2022
In Q4, MYRIAD GENETICS, INC. had in-house lobbyists. The report was filed on Jan. 20, 2023.
Original Filing: 301437370.xml
Lobbying Issues
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" (HR 4128 / S 2209)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
FY23 House and Senate MilCon/VA appropriations; access to depression treatments for veterans
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Telehealth provisions following PHE; HR6202/S3593 - provisions requiring in person visits prior to ordering lab tests
Legislation on best practices for pharmacogenomic testing; S4633
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2022
In Q3, MYRIAD GENETICS, INC. had in-house lobbyists. The report was filed on Oct. 19, 2022.
Original Filing: 301411241.xml
Lobbying Issues
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" (HR 4128 / S 2209)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
FY23 House and Senate MilCon/VA appropriations; access to depression treatments for veterans
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Mental health legislation; no draft, no bill introduced - access to genetic testing for mental health treatment decisions
Telehealth provisions following PHE; HR6202/S3593 - provisions requiring in person visits prior to ordering lab tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2022
In Q2, MYRIAD GENETICS, INC. had in-house lobbyists. The report was filed on July 20, 2022.
Original Filing: 301395164.xml
Lobbying Issues
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" (HR 4128 / S 2209)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
FY23 House and Senate MilCon/VA appropriations; access to depression treatments for veterans
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Mental health legislation; no draft, no bill introduced - access to genetic testing for mental health treatment decisions
Telehealth provisions following PHE; HR6202/S3593 - provisions requiring in person visits prior to ordering lab tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2022
In Q1, MYRIAD GENETICS, INC. had in-house lobbyists. The report was filed on April 20, 2022.
Original Filing: 301367183.xml
Lobbying Issues
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" (HR 4128 / S 2209)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
FY23 House and Senate MilCon/VA appropriations; access to depression treatments for veterans
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Mental health legislation; no draft, no bill introduced - access to genetic testing for mental health treatment decisions
Telehealth provisions following PHE; HR6202/S3593 - provisions requiring in person visits prior to ordering lab tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2021
In Q4, MYRIAD GENETICS, INC. had in-house lobbyists. The report was filed on Jan. 20, 2022.
Original Filing: 301338609.xml
Lobbying Issues
Section 216(a) of PL 113-93 (Protecting Access to Medicare Act of 2014; aka PAMA) - payment of laboratory tests in Medicare
Lobbying Issues
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" (HR 4128 / S 2209)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
FY22 House and Senate MilCon/VA appropriations (HR 4355); access to depression treatments for veterans
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Mental health legislation; no draft, no bill introduced - access to genetic testing for mental health treatment decisions
Telehealth provisions following PHE; HR 6202/no Senate number - provisions requiring in person visits prior to ordering lab tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2021
In Q3, MYRIAD GENETICS, INC. had in-house lobbyists. The report was filed on Oct. 20, 2021.
Original Filing: 301310354.xml
Lobbying Issues
Section 216(a) of PL 113-93 (Protecting Access to Medicare Act of 2014; aka PAMA) - payment of laboratory tests in Medicare
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" (HR 4128 / S 2209)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
FY22 House and Senate MilCon/VA appropriations (HR 4355); access to depression treatments for veterans
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Mental health legislation; no draft, no bill introduced - access to genetic testing for mental health treatment decisions
Telehealth provisions following PHE; no bill introduced - provisions requiring in person visits prior to ordering lab tests
2nd Quarter, 2021
In Q2, MYRIAD GENETICS, INC. had in-house lobbyists. The report was filed on July 20, 2021.
Original Filing: 301288716.xml
Lobbying Issues
Section 216(a) of PL 113-93 (Protecting Access to Medicare Act of 2014; aka PAMA) - payment of laboratory tests in Medicare
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" (HR 4128 / S 2209)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
FY22 House and Senate MilCon/VA appropriations (HR 4355); access to depression treatments for veterans
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2021
In Q1, MYRIAD GENETICS, INC. had in-house lobbyists. The report was filed on April 20, 2021.
Original Filing: 301260665.xml
Lobbying Issues
Section 216(a) of PL 113-93 (Protecting Access to Medicare Act of 2014; aka PAMA) - payment of laboratory tests in Medicare
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" - not yet introduced
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Implementation of Public Law No: 116-171 (Commander John Scott Hannon Veterans Mental Health Care Improvement Act of 2019) - access to veterans mental health care services
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FY21 House and Senate MilCon/VA appropriations (no bill #s); access to depression treatments for veterans
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2020
In Q4, MYRIAD GENETICS, INC. had in-house lobbyists. The report was filed on Jan. 20, 2021.
Original Filing: 301239824.xml
Lobbying Issues
PL 113-93, Protecting Access to Medicare Act of 2014; implementation of Medicare payment changes for clinical laboratory tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Regulation of laboratory developed tests "Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2020" - HR 6102/S 3404
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
CARES Act (PL 116-136), provisions concerning COVID testing, laboratories and unemployment insurance
Legislation addressing barriers to the adoption of pharmacogenomic testing; not introduced
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Public Law No: 116-171, Commander John Scott Hannon Veterans Mental Health Care Improvement Act of 2019, issues related to suicide reduction
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2020
In Q3, MYRIAD GENETICS, INC. had in-house lobbyists. The report was filed on Oct. 20, 2020.
Original Filing: 301221931.xml
Lobbying Issues
Medicare coverage policies for mental health genetic tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Regulation of laboratory developed tests "Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2020" - HR 6102/S 3404
Provisions relating to laboratories in PL 115-271 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act; Section 8122
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
CARES Act (PL 116-136), provisions concerning COVID testing, laboratories and unemployment insurance
"COVID 4.0," legislation address impact of pandemic; provisions relating to laboratories and mental health providers
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2020
In Q2, MYRIAD GENETICS, INC. had in-house lobbyists. The report was filed on July 20, 2020.
Original Filing: 301197407.xml
Lobbying Issues
Medicare coverage policies for mental health genetic tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Regulation of laboratory developed tests e.g. pharmacogenomics LDTs - discussion draft in House - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2020" - HR 6102/S 3404
Provisions relating to laboratories in PL 115-271 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act; Section 8122
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
CARES Act (PL 116-136), provisions concerning COVID testing, laboratories and unemployment insurance
"COVID 4.0," legislation not yet introduced to address impact of pandemic; provisions relating to laboratories and mental health providers
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2020
In Q1, MYRIAD GENETICS, INC. had in-house lobbyists. The report was filed on April 20, 2020.
Original Filing: 301176180.xml
Lobbying Issues
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA - PL 113-93); payment of laboratory tests
Medicare coverage policies for mental health genetic tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Regulation of laboratory developed tests e.g. pharmacogenomics LDTs - discussion draft in House - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2020" - HR 6102/S 3404
Provisions relating to laboratories in PL 115-271 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act; Section 8122
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
FY20 HHS Appropriations bill regarding CMS coverage policies for mental health genetic tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 1895, the Lower Health Care Costs Act - Title I, Ending Surprise Medical Bills
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2019
In Q4, MYRIAD GENETICS, INC. had in-house lobbyists. The report was filed on Jan. 21, 2020.
Original Filing: 301127181.xml
Lobbying Issues
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA - PL 113-93); payment of laboratory tests
Medicare coverage policies for mental health genetic tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Regulation of laboratory developed tests e.g. pharmacogenomics LDTs - discussion draft in House - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act"; no HR #
Provisions relating to laboratories in PL 115-271 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act; Section 8122
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
FY20 HHS Appropriations bill regarding CMS coverage policies for mental health genetic tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 1895, the Lower Health Care Costs Act - Title I, Ending Surprise Medical Bills
3rd Quarter, 2019
In Q3, MYRIAD GENETICS, INC. had in-house lobbyists. The report was filed on Oct. 21, 2019.
Original Filing: 301077724.xml
Lobbying Issues
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA - PL 113-93); payment of laboratory tests
Medicare coverage policies for mental health genetic tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Regulation of laboratory developed tests e.g. pharmacogenomics LDTs - discussion draft in House - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act"; no HR #
Provisions relating to laboratories in PL 115-271 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act; Section 8122
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
FY20 HHS Appropriations bill regarding CMS coverage policies for mental health genetic tests
Lobbying Issues
S. 1895, the Lower Health Care Costs Act - Title I, Ending Surprise Medical Bills
2nd Quarter, 2019
In Q2, MYRIAD GENETICS, INC. had in-house lobbyists. The report was filed on July 22, 2019.
Original Filing: 301058614.xml
Lobbying Issues
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA - PL 113-93); payment of laboratory tests
Medicare coverage policies for mental health genetic tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Regulation of laboratory developed tests - discussion draft in House - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act"; no HR #
Provisions relating to laboratories in PL 115-271 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act; Section 8122
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Legislation to reform Section 101 of the Patent Act concerning patent eligibility; no bill introduced yet, only draft language
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
FY20 HHS Appropriations bill regarding CMS coverage policies for mental health genetic tests
Lobbying Issues
S. 1895, the Lower Health Care Costs Act - Title I, Ending Surprise Medical Bills
1st Quarter, 2019
In Q1, MYRIAD GENETICS, INC. had in-house lobbyists. The report was filed on April 22, 2019.
Original Filing: 301038377.xml
Lobbying Issues
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA - PL 113-93); payment of laboratory tests
Medicare coverage policies for mental health genetic tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Regulation of laboratory developed tests - discussion draft in House - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act"; no HR #
Provisions relating to laboratories in PL 115-271 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act; Section 8122
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Legislation to reform Section 101 of the Patent Act concerning patent eligibility; no draft or bill introduced yet
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2018
In Q4, MYRIAD GENETICS, INC. had in-house lobbyists. The report was filed on Jan. 22, 2019.
Original Filing: 301014886.xml
Lobbying Issues
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA)(PL 113-93); payment, coding and coverage for laboratory tests
Crosswalk payment for BRCA CPT codes
Coverage for personalized medicine tests for the treatment of major depressive disorder
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Regulation of laboratory developed tests - discussion draft in House - The Diagnostic Accuracy and Innovation Act (DAIA) and Verifying Accurate Leading-edge IVCT Development Act of 2018 (VALID); no HR #
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Potential legislation to amend statute governing patent eligibility; section 101
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2018
MYRIAD GENETICS, INC. amended a lobbying report for in-house lobbying in Q32018 on Oct. 18, 2018
Original Filing: 300988847.xml
Lobbying Issues
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA)(PL 113-93); payment, coding and coverage for laboratory tests
HR 3635, Local Coverage Determination Clarification Act of 2017; LCD process for laboratory tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Regulation of laboratory developed tests - discussion draft in House - The Diagnostic Accuracy and Innovation Act (DAIA); no HR #
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Coverage and payment of laboratory tests by the VA
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2018
In Q3, MYRIAD GENETICS, INC. had in-house lobbyists. The report was filed on Oct. 18, 2018.
Original Filing: 300988104.xml
Lobbying Issues
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA)(PL 113-93); payment, coding and coverage for laboratory tests
HR 3635, Local Coverage Determination Clarification Act of 2017; LCD process for laboratory tests
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Regulation of laboratory developed tests - discussion draft in House - The Diagnostic Accuracy and Innovation Act (DAIA); no HR #
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Coverage and payment of laboratory tests by the VA
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2018
MYRIAD GENETICS, INC. filed a lobbying registration on Sept. 5, 2018 for in-house lobbying efforts, effective Sept. 1, 2018.
Original Filing: 300981482.xml
Issue(s) they said they’d lobby about: Payment for laboratory testing by Medicare, Medicaid, VA, DoD, TRICARE, etc.
Regulation of laboratory developed tests by FDA .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate